UNAUDITED PROFORMA CONDENSED COMBINED FINANCIAL INFORMATION OF NIGHTHAWK BIOSCIENCES, INC.NightHawk Biosciences, Inc. • June 6th, 2022 • Pharmaceutical preparations
On December 20, 2021, NightHawk Biosciences, Inc. (formerly Heat Biologics, Inc. “Heat”) (“NightHawk” or the “Company”) entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) by and among Heat, Heat Acquisition Sub 1, Inc., a Delaware corporation and wholly owned subsidiary of Heat (“Merger Sub”), and Elusys Therapeutics, Inc., a Delaware corporation (“Elusys”), which provides for, among other things, the merger of Merger Sub with and into Elusys, with Elusys continuing as the surviving entity as a wholly owned subsidiary of Heat (the “Merger”). The Merger contemplated by the Merger Agreement (the “Closing”) closed on April 18, 2022 (the “Closing Date”).
